ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,0835
0,05%
Bitcoin
108.164,49
4,90%
Brent Oil
79,715
-0,62%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vaxart Inc (VXRT)

  7. Vaxart Inc (VXRT) Notícias

VXRT

Vaxart (VXRT)

Vaxart Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VXRT
DataHoraFonteTítuloCódigoCompanhia
14/01/202515:40AllPennyStocks.comThis California-Based Biotech Found Massive Success Following DSMB ApprovalNASDAQ:VXRTVaxart Inc
14/01/202510:00GlobeNewswire Inc.Vaxart Highlights Progress of COVID-19, Norovirus and Influenza ProgramsNASDAQ:VXRTVaxart Inc
13/01/202521:55GlobeNewswire Inc.Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical TrialNASDAQ:VXRTVaxart Inc
31/12/202418:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VXRTVaxart Inc
17/12/202418:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VXRTVaxart Inc
02/12/202418:01GlobeNewswire Inc.Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
19/11/202410:00GlobeNewswire Inc.Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VXRTVaxart Inc
13/11/202418:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VXRTVaxart Inc
13/11/202418:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
07/11/202410:00GlobeNewswire Inc.Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13NASDAQ:VXRTVaxart Inc
24/10/202409:00GlobeNewswire Inc.Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024NASDAQ:VXRTVaxart Inc
15/10/202409:00GlobeNewswire Inc.Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet NeedNASDAQ:VXRTVaxart Inc
08/10/202417:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VXRTVaxart Inc
30/09/202417:12GlobeNewswire Inc.Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
28/08/202409:00GlobeNewswire Inc.Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical DysplasiaNASDAQ:VXRTVaxart Inc
08/08/202417:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
02/08/202409:00GlobeNewswire Inc.Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8NASDAQ:VXRTVaxart Inc
17/06/202417:05GlobeNewswire Inc.Vaxart Provides Business UpdateNASDAQ:VXRTVaxart Inc
13/06/202420:07GlobeNewswire Inc.Vaxart Announces $40 Million Underwritten Offering of Common StockNASDAQ:VXRTVaxart Inc
13/06/202417:15GlobeNewswire Inc.Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateNASDAQ:VXRTVaxart Inc
13/05/202417:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VXRTVaxart Inc
13/05/202408:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:VXRTVaxart Inc
07/05/202409:00GlobeNewswire Inc.Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13NASDAQ:VXRTVaxart Inc
30/04/202409:00GlobeNewswire Inc.Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersNASDAQ:VXRTVaxart Inc
27/03/202409:00GlobeNewswire Inc.Vaxart to Present at World Vaccine Congress Washington 2024 on April 3NASDAQ:VXRTVaxart Inc
14/03/202417:01GlobeNewswire Inc.Vaxart Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:VXRTVaxart Inc
14/03/202408:41IH Market NewsU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices ClimbNASDAQ:VXRTVaxart Inc
07/03/202410:00GlobeNewswire Inc.Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14NASDAQ:VXRTVaxart Inc
06/03/202410:00GlobeNewswire Inc.Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorNASDAQ:VXRTVaxart Inc
13/02/202419:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VXRTVaxart Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VXRT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
FNAM11
Fundo Invest Amazonia Fi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados